JelikaLite to Launch Autism Therapy Device, Offers Early Access Waitlist
In addition, if you apply to join JelikaLite waitlist by filling in the form on this page you will receive an ADDITIONAL $250 off the final anticipated price.
Please note that NO PAYMENT IS REQUIRED at this time. By filling in the form you will merely be expressing interest in your child receiving this therapy.
Once the device has been approved by the FDA and made available to public you will be connected to a local participating physician to get your child evaluated to determine whether Cognilum is appropriate for them and, if qualified, to receive the treatment.
JelikaLite is a medical technology company with focus on pediatric neurological health using non-invasive novel therapies. It has recently received breakthrough device designation from the US Food and Drug Administration (FDA) for its Cognilum System.
Cognilum, a Non-Invasive Treatment for Autism
Cognilum is a transformational neuromodulation platform combining non-invasive wearable brain stimulation medical device with machine learning personalization, rapidly improving children’s speech, responsiveness and socialization.
Cognilum provides treatment through transcranial photobiomodulation (tPBM) which uses gentle LED light to help improve brain function, communication and daily living skills.
To date, JelikaLite has conducted 3 clinical studies showing improvement in children’s communications and is currently starting a Pivotal clinical trial (required for FDA approval).
JelikaLite is also at present time collecting interest from parents in receiving Cognilum treatment for their children – once it is FDA approved. No payment is required at this time.
Cognilum medical device will be regulated by the FDA prior to launch.
SAFETY & CONVENIENCE
- Safe – received FDA Non-Significant Risk Device Study designation
- No known negative long term side effects
- Comfortable to wear for children with sensory issues
- Requires only 2x per week treatment, of up to 20 minutes at a time
- Received FDA Breakthrough Device Designation
- Accelerates language development *
- Promotes social interaction *
- Increases responsiveness *
HOW DOES IT WORK
The device provides treatment through transcranial photobiomodulation (tPBM). tPBM is a treatment that uses gentle LED light to help improve brain function in autistic children.
- A special device (Cognilum) shines a safe light onto your child’s head, targeting specific brain areas.
- The light passes through the skin and skull, reaching the brain.
- Inside the brain, the light helps brain cells create more energy.
- Over 80% of autistic children have mitochondrial disfunction and tPBM, with its beneficial effect on mitochondria, may improve the brain functioning.
- This extra energy supports brain cells in working better and can promote healing.
- Systemic effects: The improved cellular function can lead to various beneficial effects, such as reduced inflammation, increased blood flow, and enhanced neuroplasticity (the brain’s ability to form new connections).
- As a result, your child may experience improvements in communication, social skills, and other areas affected by Autism Spectrum Disorder.
In summary, tPBM is a non-invasive and painless treatment that uses light to help enhance brain function in children with autism, potentially leading to better overall well-being.
*These statements are based on the results of the double blind placebo controlled Phase I clinical trial and have not yet been evaluated by the FDA.
Join the Waitlist to Secure Early Access
JelikaLite will have a limited supply of the Cognilum device at its anticipated launch in 2024.
Sign up now to guarantee access and support their mission.
Exclusive Waitlist Benefits: $3,750 for 24 sessions — $750 discount off anticipated price of $4,500 for 24 sessions
PLUS AN ADDITIONAL DISCOUNT OF $250 OFF THE FINAL PRICE IF YOU SIGN UP VIA THE FORM BELOW.
No payment required today. Guaranteed access after medical approval*
*Upon Cognilum launch, you will be contacted by a local physician to schedule an evaluation for your child, in order to determine whether Cognilum is appropriate for them. Please note that price may change.
Frequently Asked Questions
Cognilum is currently going through certification. What does this mean?
In broad terms, this means we are currently demonstrating to the FDA that there is appropriate clinical and safety evidence for Cognilum to be used as a medical device for the amelioration of certain symptoms associated with ASD. This demonstration requires extensive clinical trials and safety testing. Until this process is completed, we are unable to provide you with the Cognilum, and Cognilum remains unavailable to purchase. We expect this process to be completed in 2024. At launch, we will provide our exclusive waitlist members the opportunity to confirm that Cognilum, as approved, is an appropriate medical treatment for their child.
Will Cognilum cure conditions or alleviate symptoms?
Cognilum is not designed to cure ASD. However, Cognilum is designed and intended to alleviate a range of psychological symptoms that are commonly experienced by children diagnosed with such conditions including inability to communicate, repetitive behaviors, social anxiety and problematic behaviors (such as bolting and self-harm). In some cases, Cognilum may also enhance the child’s physical stamina and dexterity. Once Cognilum is approved, waitlist members will have early access to assess whether their children’s symptoms are a match for those approved for treatment with Cognilum- and will be able to apply an exclusive discount to receive treatment.
Does the Waitlist form a commitment to buy?
My child does not have any formal clinical diagnoses. Can they still benefit from Cognilum?
Do I need to pay anything to join the Waitlist?
Is Cognilum safe?
Have you conducted efficacy research with Cognilum?
Yes, extensively. We have run more than 2 years of tests on Cognilum itself, and this builds on decades of research into the underlying neuro technology, photobiomodulation and its mechanism of action. These tests range across safety, efficacy, ergonomics and more. We are actively updating our website to provide further details on these trials, the results are awaiting publications in journals. We also have ongoing clinical trials right now. If you want to learn more, or to participate in these clinical trials – please reach out at email@example.com.
How much does treatment with Cognilum cost?
What ages is Cognilum appropriate for?
The final age range will be determined by FDA clearance. To date, JelikaLite has run clinical studies with children up to 9 years of age. There were other studies that showed tPBM being effective in improving communication skills and responsiveness in older autistic individuals. We plan to conduct additional clinical studies and get FDA approval for older children, teenagers and young adults. Please join our waitlist and we will know once either clinical trials open up or the product for older children becomes available.
Will Cognilum be covered by insurance?
I have more questions, who do I contact?
If you have any further questions, please reach out to firstname.lastname@example.org or go to www.jelikalite.com
JelikaLite at BRAIN Synchrony Symposium
More on photobiomodulation for autism and other neurological disorders – related BRAIN Synchrony Symposia
RESOURCES & PUBLICATIONS